Abstract
Purpose: Materials and Methods: From 1995 to 2003, 42 patients who underwent surgery due to infiltrative ductal carcinoma without lymph node metastasis were included in the study. 25 (59.5%) of these patients were treated with modified radical mastectomy (MRM), while 17 (40.5%) were subjected to breast conserving (BC) surgery. All patients with BC surgery received radiotherapy and all patients with T2 and T3 tumors received antracycline based adjuvant chemotherapy. Based on their estrogen receptor status, they were also given tamoxifen. Patients had follow-ups every three months in the first year of post-operation and every six months thereafter. Results: Both groups of patients had periodic follow-ups over the course of the study (6 - 1005 months). Both groups were similar in terms of age, tumor localization, menopausal status and number of dissected lymph nodes. One (5.8%) of the patients in BC group had local recurrence and was treated with mastectomy. Another patient had lung and liver metastases in the 80th month. In the MRM group 4 (16%) patients had contra-lateral breast cancer between 6 and 24 months, postoperatively. None of the patients died in the both groups. Conclusion: In early stage of breast cancer, BC surgery was found to be as safe as MRM in terms of its post-operative disease-free nature and its total survival rate.
Keywords:
Breast conserving surgery, breast cancer, modified radical mastectomy
References
1
Ewert Z, Duffy S. Incidence of female breast cancer in relation to prevalence of risk factors in Denmark. Int J Cancer, 1994; 56:783-7.
2
Nystrom L, Rutqvist LE, Wall S, et al. Breast cancer screening with mammography: over-view of Swedish randomized trials. Lancet, 1993; 341:973-6.
3
Halsted WS. The results of radical operations for the cure of carcinoma of the breast. Ann Surg, 1907;46:1-19.
4
Fisher B, Bauer M, Margolese R, et al. Five-year results of a randomized clinical trial comparing total mastectomy with or without radiation in the treatment of breast cancer. N Engl J Med, 1985;312:665-673.
5
Fisher B. Lumpectomy versus quadrenectomy for breast conservation: a critical appraisal. Eur J Cancer, 1995;31A:1567-1569.
6
Saccini A, Luini A, Tana S, et al. Quantitative and qualitative cosmetic evaluation after conservative treatment for breast cancer. Eur J Cancer, 1991;27:1395-1400.
7
Yılmazer N, Aydıner A, Özkan S, ve ark. Total mastektomi ve meme koruyucu tedavide beden imajı ve benlik saygısının karşılaştırılması. Türk Onkoloji Dergisi, 1993;8:1449-1453.
8
Liljegren G, Holmberg L, Westman G and Uppsala-Orebro Breast Cancer Study Group. The cosmetic outcome in early breast cancer treated with sector resection with or without radiotherapy. Eur J Cancer, 1993;29A:2083-2089.
9
Moro G, Ciambellotti E. Evaluation of the esthetic results of conservative treatment of breast cancer. Tumori, 1993;79:258-261.
10
Amichetti M, Busana L, Caffo O. Long-term cosmetic outcome and toxicity in patients treated with quadrenectomy and radiation therapy for early-stage breast cancer. Oncology, 1995;52:177-181.
11
Kenny P, King LM, Shiell A, et al. Early stage breast cancer: cost and quality of life one year after treatment by mastectomy or conservative surgery and radiation therapy. Breast, 2000;9:37-44.
12
Harris JR, Hellman S. The Results of Primary Radiation Therapy for Early Breast Cancer at the Joint Center for Radiation Therapy. Philadelphia: JB Lippincott, 1983.
13
Montague ED. Conservation surgery and radiation therapy in the treatment of operable breast cancer. Cancer, 1984; 53: 700-4.
14
Danoff BF, Pajak TF, Solin LJ, et al. Excisional biopsy, axillary node dissection and definitive radiotherapy for stages I and II breast cancer. Int J Radiat Oncol Biol Phys, 1985; 11: 479-83.
15
Bland KI, Menck HR, Scott-Conner CE, et al. The national cancer data base 10-year report on the results of a large nonrandomized comparison of breast preservation and modified radical mastectomy. Cancer, 1998;83:2649-58.
16
Winchester DJ, Menck HR, Winchester DP. The National Cancer Data Base report on the results of a large nonrandomized comparison of breast preservation and modified radical mastectomy. Cancer, 1997;80:162-7.
17
Fisher B, Anderson S, Redmond CK, et al. Reanalysis and results after 12 years of followup in a randomized clinical trial comparing total mastectomy with lumpectomy with or without irradiation in the treatment of breast cancer. N Engl J Med, 1995;333:1456-61.
18
Fisher B, Anderson S, Bryant J, et al. Twentyyear follow-up of a randomized trial comparing total mastectomy, lumpectomy and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med, 2002;347:1233-41.
19
Dolan JT, Granchi TS. Low rate of breast conservation surgery in large urban hospital serving the medical indigent. Am J Surg, 1998;176:520-524.
20
Lazovich D, Solomon CC, Thomas DB, et al. Breast conservation therapy in the United States following the 1990 National Institutes of Health Consensus Development Conference on the treatment of patients with early stage invasive breast carcinoma. Cancer, 1999;86:628-637.
21
Albain KS, Green SR, Lichter AS, et al. Influence of patient characteristics, socioeconomic factors, geography, and systemic risk on the use of breast-sparing treatment in women enrolled in adjuvant breast cancer studies: an analysis of two intergroup trials. J Clin Oncol, 1996;14:3009-3017
22
Desch CE, Penberthy LT, Hillner BE, et al. A sociodemographic and economic comparison of breast reconstruction, mastectomy, and conservative surgery. Surgery, 1999;125:441-447.
23
Gilligan MA, Kneusel RT, Hoffmann RG, et al. Persistent differences in sociodemographic determinants of breast conserving treatment despite overall increased adoption. Med Care, 2002;40:181-189.
24
Hiotis K, Wei Y, Sposto R, et al. Predictors of breast conservation therapy: size is not all the matters. Cancer, 2005;103:892-9.
25
Vlastos G, Mirza NQ, Meric F, et al. Breast conservation therapy as a treatment option for elderly. The M.D. Anderson experience. Cancer, 2001;92:1092-1100.
26
Mandelblatt JS, Hadley J, Kerner JF, et al. Patterns of breast carcinoma treatment in older women: patient preference and clinical and physical influences. Cancer, 2000;89:561-573.
27
Madan AK, Aliabadi-Wahle S, Beech DJ. Age bias: a cause of underutilization of breast conservation treatment. J Cancer, Educ 2001;16:29-32.
28
Sarrazin D, Le MG, Arriagada R, et al. Ten-year results of a randomized trial comparing a conservative treatment to mastectomy in early breast cancer. Radiother Oncol, 1989; 14: 177-84.
29
Veronesi U, Luini A, Galimberti V, et al. Conservation approaches for the management of stage I/II carcinoma of the breast: Milan Cancer Institute trials. World J Surg, 1994; 18: 70-5.
30
Fisher B, Redmond C. Lumpectomy for breast cancer: an update of the NSABP experience. J Natl Cancer Inst Monogr, 1992; 11: 7-13.
31
Straus K, Lichter A, Lippman M, et al. Results of the National Cancer Institute early breast cancer trial. J Natl Cancer Inst Monogr 1992; 11: 27-32.
32
Huston TL, Simmons RM. Locally recurrent breast cancer after conservation therapy. Am J Surg, 2005;189:229-35.
33
Yıldırım E, Gülben K, Berberoğlu U, ve ark. Meme koruyucu tedavi uygulanan olgularda prognostik etkenlerin analizi. Ulusal Cerrahi Dergisi, 1999;15(5):282-290.
34
Swenson KK, Decher L, Haselow R, et al. Prognostic factors after conservative surgery and radiation therapy for early stage breast cancer. Am J Clin Oncol, 1998; 21: 111-6.
35
Mirza NQ, Vlastos G, Buchholz TA, et al. Predictors of locoregional recurrence among patients with early-stage breast cancer treated with breast-conserving therapy. Annals of Surgical Oncology, 2002;9:256-265.
36
Fisher B, Redmond C, Dimitrov NV, et al. A randomized clinical trial evaluating sequential methotrexate and fluorouracil in the treatment of patients with node-negative breast cancer who have estrogen-receptor-negative tumors. N Engl J Med, 1989; 320: 473-8.
37
Fisher B, Constantino J, Redmond C, et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med, 1989; 320: 479-84.
38
Fisher B, Redmond C, Poisson R, et al. Eightyear results of a randomized clinical trial comparing total mastectomy and lumpectomy with or without irradiation in the treatment of breast cancer. N Engl J Med, 1989; 320: 822-8.
39
Borger JH. The impact of surgical and pathological findings on radiotherapy of early breast cancer. Radiother Oncol, 1991; 22: 230-6.
40
DiBiase S, Komarnicky LT, Schwartz GF, et al. The number of positive margins influences the outcome of women treated with breast preservation for early stage breast carcinoma. Cancer, 1998; 82: 2212-20.
41
Smitt MC, Nowels KW, Zdeblick MJ, et al. The importance of the lumpectomy surgical margin status in long term results of breast conservation. Cancer, 1995; 76: 259-67.
42
Schnitt SJ, Abner A, Gelman R, et al. The relationship between microscopic margins of resection and the risk of local recurrence in patients with breast cancer treated with breast-conserving surgery and radiation therapy. Cancer, 1994; 74: 1746-51.
43
Kemperman H, Borger J, Hart A, et al. Prognostic factors for survival after breast conserving therapy for stage I and II breast cancer. The role of local recurrence. Eur J Cancer, 1995; 31A: 690-8
44
van Dongen JA, Bartelink H, Fentiman IS, et al. Randomized clinical trial to assess the value of breast-conserving therapy in stage I and II breast cancer, EORTC 10801 trial. J Natl Cancer Inst Monogr, 1992; 11: 15-8.
45
Whelan T, Clark R, Roberts R, et al. Ipsilateral breast tumor recurrence post lumpectomy is predictive of subsequent mortality: results from a randomized trial. Int J Radiat Oncol Biol Phys, 1994; 30: 11-6.
46
Claus EB, Schildkraut JM, Thompson WD, et al. The genetic attributable risk of breast and ovarian cancer. Cancer, 1996;77:2318-24.
47
Verkooijen HM, Chappuis PO, Rapiti E, et al. Impact of familial risk factors on management and survival of early-onset breast cancer: a population- based study. Br J Cancer, 2006;94:231-8.
48
Seynaeve C, Verhoog LC, van de Bosch LM, et al. Ipsilateral breast tumour recurrence in hereditary breast cancer following breast-conserving therapy. Eur J Cancer, 2004;40:1150-8.
49
Kirova YM, Stoppa_Lyonnet D, Savignoni A, et al. Risk of breast cancer recurrence and contralateral breast cancer in relation to BRCA1 and BRCA2 mutation status following breast-conserving surgery and radiotherapy. Eur J Cancer, 2005;41:2301-11
